


Buprenorphine cuts neonatal abstinence syndrome treatment length by nearly half

May 4 2017



Dr. Walter Kraft of Thomas Jefferson University and co-investigator Dr. Adeniyi-Jones of Nemours/Alfred I. duPont Hospital for Children. Credit: Thomas Jefferson University

Findings of a phase 3 clinical trial being presented at the 2017 Pediatric

Academic Societies Meeting show that buprenorphine is just as safe and more effective than morphine when used to treat newborns suffering withdrawal symptoms after prenatal drug exposure.

Researchers will present the study, "A Randomized Controlled Trial of Sublingual Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome," on Sunday, May 7, at the Moscone West Convention Center in San Francisco. The [randomized controlled trial](#) known as B-BORN (Blinded Buprenorphine OR Neonatal morphine solution trial) will be published online in the *New England Journal of Medicine* on May 4.

More than half of infants exposed to opioids during pregnancy require pharmacologic [treatment](#) for [withdrawal symptoms](#) of [neonatal abstinence syndrome](#), such as seizures and respiratory and digestive problems, that make it difficult for them to adequately eat and sleep. Traditional treatment for these newborns, most often with morphine, requires lengthy hospital stays.

The B-BORN study followed up earlier-phase clinical [trials](#) that suggested buprenorphine could reduce the length of treatment and hospitalization needed for babies with neonatal abstinence syndrome. Researchers enrolled 63 infants who were born exposed to opioids—97 percent of whom were exposed to methadone. They compared sublingual buprenorphine to oral morphine treatment outcomes and found similarly promising results.

"This study has large public health implications, since the rate of neonatal abstinence has increased almost 5-fold over the past 15 years," said lead author Walter Kraft, MD, Professor of Pharmacology, Medicine & Surgery at Thomas Jefferson University. In some hospitals, he said, NAS accounts for more than 20 percent of all days patients spend in the [neonatal intensive care](#) unit.

Buprenorphine was associated with a 42 percent decrease in the length of treatment compared to standard morphine, according to the trial. Average length of treatment needed for babies given buprenorphine was 15 days compared with 28 days using morphine, he said, while length of hospital stays for babies treated with buprenorphine averaged 21 days, versus 34.5 days for those treated with [morphine](#).

In addition, Dr. Kraft said, there were no readmissions or increased need for "rescue" therapy with phenobarbital when symptoms didn't initially subside. Buprenorphine has a well-established safety record in adults, he said, and no safety issue was identified in this trial. Babies' respiratory rate, liver function and other health indicators, for example, were similar in both groups.

"Our findings provide evidence that [buprenorphine](#) can safely and effectively serve to reduce the significant burden of neonatal abstinence syndrome on individual infants and families, and hospitals," he said.

Dr. Kraft will present the study, "A Randomized Controlled Trial of Sublingual Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome," at 8:45 a.m. Sunday May 7.

More information: Walter K. Kraft et al, Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome, *New England Journal of Medicine* (2017). DOI: 10.1056/NEJMoa1614835

Provided by American Academy of Pediatrics

Citation: Buprenorphine cuts neonatal abstinence syndrome treatment length by nearly half (2017, May 4) retrieved 19 April 2024 from <https://medicalxpress.com/news/2017-05-buprenorphine-neonatal-abstinence-syndrome->

[treatment.html](#)

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.